• FBXO22 Ligand Development Expands Targeted Protein Degradati

  2026-07-01

  The referenced study introduces novel chemical probes for FBXO22, an E3 ubiquitin ligase, enabling its selective recruitment and degradation in targeted protein degradation (TPD) workflows. This work broadens TPD strategies beyond the traditional reliance on CRBN and VHL, offering new molecular tools and mechanistic insights for cancer and protein homeostasis research.

• Elevating Src Kinase Research: Strategic Use of PP 3 Control

  2026-07-01

  This thought-leadership article explores how 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP 3) establishes new benchmarks for specificity and interpretability in Src kinase signaling pathway research. Integrating recent mechanistic insights from ROS-mediated vascular contraction, we delineate how rigorous negative controls, such as APExBIO’s PP 3, empower translational researchers to deconvolute signaling events and drive reproducible, clinically relevant discoveries.

• Angiotensin 1/2 (5-7): Precision RAS Peptide for Applied Res

  2026-06-30

  Angiotensin 1/2 (5-7) enables high-resolution modeling of blood pressure regulation and viral entry mechanisms, bridging renin-angiotensin system research with COVID-19 pathogenesis. Its unmatched purity and solubility profile make it the go-to peptide for reproducible, advanced experimental workflows.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody: Technical Workflows

  2026-06-30

  The HRP Goat Anti-Rabbit IgG (H+L) Antibody addresses practical needs in detecting rabbit primary antibodies across ELISA, Western blot, and immunohistochemistry by providing affinity-purified, HRP-conjugated specificity and robust signal amplification. It is not suitable for diagnostic or clinical applications, nor for workflows requiring detection of non-rabbit primaries or subclasses outside total IgG (H+L).

• SCH772984: Redefining ERK1/2 Inhibition for Tumor Radiosensi

  2026-06-29

  Explore how SCH772984, a potent ERK1/2 inhibitor, uniquely enables targeted MAPK/ERK pathway inhibition and informs strategies to overcome radioresistance in cancer models. Gain new insights into protocol design, translational relevance, and practical assay optimization.

• Hybrid Hydrogel Boosts Erythromycin Efficacy in Bacterial Ke

  2026-06-29

  The referenced study introduces a thermosensitive polyhedral oligomeric silsesquioxane (POSS) hybrid hydrogel system that enhances ocular delivery and antibacterial efficacy of erythromycin for treating bacterial keratitis. By improving drug solubility, ocular surface retention, and biocompatibility, this formulation demonstrates superior therapeutic outcomes in a preclinical model, with practical implications for future ophthalmic drug development.

• Linoleic Acid (C18:2): Applied Workflows for Oxidative Stres

  2026-06-28

  Linoleic Acid (C18:2(9Z,12Z)) is indispensable for modeling cellular redox balance, membrane fluidity, and nutritional deficiency in vitro. Discover protocol optimizations, troubleshooting strategies, and new translational research avenues leveraging APExBIO’s high-purity product.

• Angiotensin II in Vascular Remodeling: Protocols and Advance

  2026-06-27

  Harnessing Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) enables high-fidelity modeling of hypertension, vascular injury, and aortic aneurysm in both cell and animal systems. This guide distills advanced workflows, practical troubleshooting, and reference-driven innovations to optimize applied vascular research using APExBIO’s Angiotensin II.

• Applied Workflows with Angiotensin 1/2 (5-7) in RAS and Vira

  2026-06-26

  Angiotensin 1/2 (5-7) empowers high-precision studies of blood pressure regulation and emerging viral mechanisms. This guide distills actionable protocols, troubleshooting insights, and cross-domain applications, making it indispensable for researchers navigating the intersection of renin-angiotensin system and SARS-CoV-2 pathogenesis.

• RRP Extracts Restore Hepatic Lipid Metabolism in Liver IRI M

  2026-06-26

  The referenced study reveals that Radix Rehmanniae Praeparata (RRP) extracts ameliorate hepatic ischemia-reperfusion injury (HIRI) in mice by restoring lipid metabolism in hepatocytes. Mechanistically, RRP activates AMPK, inhibits SREBP2-mediated cholesterol synthesis, and promotes LXRα-driven cholesterol efflux, offering new insights for therapeutic intervention and experimental protocol design.

• Elevating Src Kinase Pathway Research: Rigor, Controls, and

  2026-06-25

  This thought-leadership article examines the pivotal role of rigorously validated negative controls—specifically PP 3 (1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine)—in dissecting Src kinase signaling mechanisms. Integrating recent mechanistic insights from vascular biology, we provide strategic guidance for translational researchers seeking to distinguish true kinase inhibitor effects from confounders. The discussion references newly published evidence on NADPH oxidase-derived ROS and their selective activation of L-type Ca2+ channels, highlighting the evolving landscape of protein tyrosine kinase inhibition research.

• BMX-IN-1: Advanced BMX Kinase Inhibitor for Targeted Researc

  2026-06-25

  BMX-IN-1 delivers high-selectivity, irreversible BMX kinase inhibition, enabling precise investigation of cell signaling in cancer and infectious disease models. Its robust performance in apoptosis induction, cell cycle arrest, and host-pathogen studies positions it as a versatile tool for translational research.

• Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit

  2026-06-24

  The Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit addresses the challenge of high-resolution separation of small proteins and peptides (1–10 kDa), which are not efficiently resolved by standard Tris-glycine SDS-PAGE. It is intended for research workflows focused on low molecular weight protein and peptide analysis, not for diagnostic or clinical use.

• MCL-1’s Canonical Role in Breast Cancer Apoptosis Dependency

  2026-06-23

  This study demonstrates that breast cancer’s reliance on MCL-1 is fundamentally due to its canonical anti-apoptotic function, with tumor regression upon MCL-1 loss requiring intact BAX/BAK pathways. These findings clarify MCL-1’s mechanistic importance and have implications for the development and clinical use of BH3-mimetic therapeutics targeting apoptosis regulators in breast cancer.

• Protease Inhibitor Cocktail EDTA-Free: Optimizing Protein In

  2026-06-23

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) from APExBIO empowers researchers to preserve protein integrity across phosphorylation-sensitive workflows and advanced lysosomal repair studies. Explore protocol enhancements, troubleshooting strategies, and data-driven insights that set this EDTA-free solution apart in Western blotting, co-immunoprecipitation, and kinase assays.

16257 records 1/1084 page Next 12345 下5页 Last page